On December 13, 2017, the 19th China patent award ceremony, known as " China intellectual property Oscar", was held in Beijing. The CHIPSCREEN BIOSCIENCES invention patent "benzamide histone deacetylase inhibitor with differentiation and antiproliferative activity and its medicinal preparation" (patent No.: 03139760.3) won this year's " China patent gold award" together with domestic giants Huawei and Haier. China's patent gold award is the highest award for original inventions by the government in the field of intellectual property rights in China, showing China's original level to the world.

Equal to the giants of various industries: what makes CHIPSCREEN BIOSCIENCES win the " China patent gold award"?

 "China patent gold award" is the best award for China's original technology, and the best embodiment of original technology is intellectual property rights, which is a patent. Since its establishment in 2001, CHIPSCREEN BIOSCIENCES has been adhering to the development philosophy of original, safe, effective and Chinese. It has formed a product line of many original new medicines for malignant tumors, diabetes, endocrine and autoimmune diseases, which is known as China's " pioneer of innovative medicines". Up till now, the company has applied for 115 patents for inventions worldwide and has been authorized 52. 58 applications for domestic and overseas trademarks, 31 of which have been approved for registration; And obtained 3 software copyright certificates.

The award-winning patent " benzamide histone deacetylase inhibitor with differentiation and antiproliferative activity and its medicinal preparation" (common name: Chidamide) is the world's first subtype selective histone deacetylase oral inhibitor originally created by CHIPSCREEN BIOSCIENCES, which belongs to an epigenetic regulator drug with a completely new anti-tumor mechanism and has made original scientific contributions to the research field of epigenetic regulation in the world. Chidamide is also a brand-new molecular body with global patent protection. It is a major milestone for China's local scientific team from target research, structure-based molecular design, safety evaluation to successful clinical development in the field of original chemical drugs facing the world, which not only changes the current situation that Chinese local pharmaceutical enterprises lack original drugs, but also represents a significant improvement in China's overall scientific research level and core technology. It symbolizes that China's drug research and development has gradually entered an independent innovation stage with the same level as or even ahead of developed countries from imitation to high imitation. At the same time, Chidamide is the first drug to treat T-cell lymphoma in our country. After 12 years of research and development, it was approved for sale by CFDA in December 2014 and included in the new national health care catalog in July this year, which not only changed the current situation of drug-free PTCL patients in China and filled the blank of Chinese PTCL treatment drugs, but also meant that Chinese PTCL patients used innovative drugs with the latest mechanism of action in the world when the burden was reduced to 1/10, bringing them better curative effect and safer survival benefits. In addition, Chidamide has realized that license US pharmaceutical enterprises to use patented technology for the first time in the history of China's pharmaceutical industry and have jointly developed international clinics. It is the first Chinese original chemical new drug approved by the US FDA to carry out clinical research in the United States. At present, Chidamide has carried out international research and development work in the United States, Japan, Taiwan, China and other places. In the future, with the further development of clinical research in Chidamide, more patients will benefit and the quality of life will be improved.

CHIPSCREEN BIOSCIENCES has always adhered to the strategy of taking intellectual property as its core and set up a patent working group with a perfect patent management system. On the one hand, it ensures the standardized operation of patent work. On the other hand, it fully encourages innovation and strengthens the protection of intellectual property. At the same time, the company has stepped up its international intellectual property layout and applied for a number of overseas invention patents. With the in-depth implementation of the intellectual property strategy, CHIPSCREEN BIOSCIENCES with more innovative power will continue to work tirelessly to promote the innovative development of China's pharmaceutical industry.

About Gold Award for Chinese Patents

The " China patent award" is the only government department award in our country dedicated to awarding patents for inventions and creations, which has been recognized by the UN World Intellectual Iroperty Organization (WIPO) with international influence. The China Patent Award was established by the state intellectual property office in 1989 and has been awarded for 19 times. The award criteria not only emphasizes the level of patent technology and innovation of the project, but also pays attention to its application in the process of market transformation. At the same time, it also put forward requirements for its protection and management. In particular, the " Gold Award for Chinese Patents" is the highest government award in the field of patents. The award-winning projects are of high quality, have outstanding contributions, and can greatly appreciate through industrialization, which are very representative reflecting the patent value, and have great contributions to the economic and social development.

Developing CHIPSCREEN BIOSCIENCES

CHIPSCREEN BIOSCIENCES is a leading enterprise of original Chinese new drugs and a modern biomedical enterprise established by a senior scientific and management team returning from the United States in 2001, which has original new drugs as its core competitiveness and is dedicated to providing patients with affordable and innovative therapeutic drugs. Since its establishment, the company has been focusing on the research and development of original small molecule drugs. Relying on the core technology of " discovery and early evaluation platform of integrated drug based on chemical genetics ", the company now has the ability to complete the research from drug targets to the development and industrialization of clinical candidate drugs with a product line of original new medicines for malignant tumors, diabetes, endocrine and autoimmune diseases.

At present, the company has two wholly-owned subsidiaries. Shenzhen Microchip Pharmaceutical co., ltd. is the production base of group's original anti-tumor chemical new drug GMP, focusing on the production of clinical samples of innovative drugs and commercial production after listing. Chengdu Microchip Pharmaceutical co., ltd. aims to meet the industrialization of original new medicines at the group headquarters. In the future, it will build an innovative medicine research and development center to further extend and expand the product line under research at the group headquarters, ensure the continuous development of new medicines by the company, and realize the strategic goal of integrating research, production and marketing of innovative medicines for Chengdu Microchip Pharmaceutical. At present, its " innovative medicine production base", " center and regional headquarters for innovative medicine research and development " are under construction.

In 2017, the company has made significant progress in preclinical and clinical research and development of several new drug product lines. Chiglitazar is the world's first original new drug for insulin resistance and cardiovascular risk in patients with type 2 diabetes, and will soon complete two large-scale phase III clinical studies in China. Theo Ronnie is a new type of three-channel targeted anti-tumor drug currently carrying out phase II clinical research. Chidamide, which has already been listed, is actively carrying out clinical studies on various diseases such as blood tumors, solid tumors and HIV. Among them, Chidamide combined with exemestane has made the fastest progress in the treatment of hormone receptor-positive advanced breast cancer, which has completed phase III clinical trials and is expected to be listed in mainland China in 2018. The United States has completed phase I clinical research and phase II clinical research on solid tumors combined with PD-1 etc. Japanese phase I clinical research has been finished, and complete PTCL+ adult T-cell leukemia / lymphoma (ATLL) orphan drug application. Taiwan is currently applying for the listing of PTCL and has been approved by Taiwan's TFDA to enter the third phase of breast cancer clinical trial, which is the second indication developed by Chidamide in Taiwan after PTCL.

In 2017, the National Ministry of Human Resources and Social Security issued a notice on the inclusion of 36 drugs in category b of the national basic medical insurance, industrial injury insurance and maternity insurance drug list. Chidamide successfully incorporated into the new national medical insurance list, which fully reflects the support of the party and the state for China's independent innovative medicines, the recognition of the vast number of experts and patients for the clinical benefits of Chidamide, and the recognition of all sectors of society for CHIPSCREEN BIOSCIENCES 's 16-year insistence on developing original new medicines. The state Council's major projects highly praised CHIPSCREEN BIOSCIENCES for its stronger originality and the spirit of Chidamide, which is a good example of the achievements in the implementation of major projects. As China's " pioneer of innovative medicine", CHIPSCREEN BIOSCIENCES has also received extensive attention from famous domestic and foreign media such as Nature, Reuters Business News, and Economy for Half an Hour.

In 2017, under the encouragement of CFDA's active pilot policy to encourage drug production enterprise groups to integrate technical resources, CHIPSCREEN BIOSCIENCES became the first group to be approved for drug listing and entrusted with production in the country. Through the obvious division of labor between the group company and its subsidiaries, the company's research and innovation capability has been further improved and the industrialization process has been further accelerated. At the same time, the company has established a quality assurance system and a drug alert system in accordance with the relevant national policies and regulations and implemented the main responsibilities of the whole chain of drug production and sales and the whole life cycle management of drugs. By November 2017, CHIPSCREEN BIOSCIENCES had completed the safety monitoring of about 3,000 patients, the largest data in the world's PTCL real-world research so far, which were highly recognized by the UMC monitoring center of the world health organization and experts in the international lymphoma treatment field.

"medicine is a special commodity that concerns human life and should be based on science rather than political, religious and commercial interests." In the future, CHIPSCREEN BIOSCIENCES will continue to struggle to promote the innovative development of China's pharmaceutical industry with the support of the national innovation policy.